Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Yuxiang Luo, Huilin Li
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8828-8828
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 135
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 86
Advances in targeting histone deacetylase for treatment of solid tumors
Mu-Qi Shi, Ying Xu, Xin Fu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 31
Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies
Ashish Shah, Aarti Choudhary, Manav Jain, et al.
3 Biotech (2024) Vol. 14, Iss. 3
Closed Access | Times Cited: 16
Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article
Nardin Wagih, Islam M. Abdel-Rahman, Nawal El‐Koussi, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 966-1010
Open Access | Times Cited: 2
Histone deacetylases and their inhibitors in inflammatory diseases
Sen-Yu Zhang, Liying Zhang, Ri Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117295-117295
Open Access | Times Cited: 13
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy
Manasa Gangadhar Shetty, Padmini Pai, Renita Esther Deaver, et al.
Pharmacological Research (2021) Vol. 170, pp. 105695-105695
Closed Access | Times Cited: 51
Lessons in Organic Fluorescent Probe Discovery
Sachin Bhausaheb Wagh, Vladimir A. Maslivetc, James J. La Clair, et al.
ChemBioChem (2021) Vol. 22, Iss. 22, pp. 3109-3139
Open Access | Times Cited: 49
Current trends in development of HDAC-based chemotherapeutics
Narges Cheshmazar, Maryam Hamzeh‐Mivehroud, Hojjatollah Nozad Charoudeh, et al.
Life Sciences (2022) Vol. 308, pp. 120946-120946
Closed Access | Times Cited: 35
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Emerging Role of HDACs in Regeneration and Ageing in the Peripheral Nervous System: Repair Schwann Cells as Pivotal Targets
Jose A. Gomez‐Sanchez, Nikiben Patel, Fernanda Martirena, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 2996-2996
Open Access | Times Cited: 25
Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response
Nan Sun, Kexin Yang, Wenzhong Yan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4802-4826
Closed Access | Times Cited: 14
Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response
Richard S. Lee, Kirti Sad, Dorelle V. Fawwal, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 4005-4005
Open Access | Times Cited: 14
Hydrazides as Inhibitors of Histone Deacetylases
María do Carmo Carreiras, José Marco‐Contelles
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13512-13533
Closed Access | Times Cited: 5
Overview of Class I HDAC Modulators: Inhibitors and Degraders
Ziqian Huang, Limei Zeng, Binbin Cheng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116696-116696
Closed Access | Times Cited: 4
Deciphering the dynamics: Exploring the impact of mechanical forces on histone acetylation
Jingyi Cai, Yudi Deng, Ziyang Min, et al.
The FASEB Journal (2024) Vol. 38, Iss. 15
Closed Access | Times Cited: 4
Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051
Yuxiang Luo, Zhaoyue Yan, Xiakun Chu, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
A critique review of fetal hemoglobin modulators through targeting epigenetic regulators for the treatment of sickle cell disease
Ala Chandu, Sivaprakash Ramalingam, Kondapalli Venkata Gowri Chandra Sekhar, et al.
Life Sciences (2025) Vol. 369, pp. 123536-123536
Closed Access
Senkyunolide A interrupts TRAF6-HDAC3 interaction to epigenetically suppress c-MYC and attenuate cholestatic liver injury
Yajing Li, Runping Liu, Jianan Li, et al.
Journal of Advanced Research (2025)
Open Access
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
Gustavo Salgado Pires, Heber Victor Tolomeu, Daniel A. Rodrigues, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 577-577
Open Access
Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia
Enqiang Liu, Yuxin Chen, Mengting Qin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116663-116663
Closed Access | Times Cited: 3
Medicinal chemistry advances in targeting class I histone deacetylases
Diaaeldin I. Abdallah, Elvin D. de Araujo, Naman H. Patel, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 757-779
Open Access | Times Cited: 8
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
Vanessa Wachholz, Al‐Hassan M. Mustafa, Yanira Zeyn, et al.
Archives of Toxicology (2021) Vol. 96, Iss. 1, pp. 177-193
Open Access | Times Cited: 19
In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods
Abdullahi İbrahim Uba, Gökhan Zengin
Amino Acids (2023) Vol. 55, Iss. 12, pp. 1709-1726
Closed Access | Times Cited: 7
Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity
Minal Mahajan, Snehal Suryavanshi, Shovonlal Bhowmick, et al.
Biophysical Chemistry (2021) Vol. 273, pp. 106588-106588
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top